RARα agonists(Retinoic acid receptor alpha agonists), RARβ2 agonists(Retinoic acid receptor beta agonists), RARγ agonists(Retinoic acid receptor gamma agonists)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesOther Diseases+ [1]

Active Indication

Facial wrinklesHyperpigmentationAcne Vulgaris+ [2]

Inactive Indication

Arthritis, PsoriaticChronic liver diseasePsoriasis of nail

Originator Organization

Allergan Ltd. (Ireland)

Active Organization

Bausch Health, Canada, Inc.

Chongqing Huapont Pharmaceutical Co. Ltd.Allergan, Inc.

+ [3]

Inactive Organization

Valeant Pharmaceuticals Australasia Pty Ltd.

Almirall SA

Actavis, Inc.

Drug Highest PhaseApproved

First Approval Date

US (13 Jun 1997),

Acne VulgarisPlaque psoriasis

Regulation-

Structure

Molecular FormulaC21H21NO2S

InChIKeyOGQICQVSFDPSEI-UHFFFAOYSA-N

CAS Registry118292-40-3

Clinical Trials associated with Tazarotene

NCT06331624 / RecruitingPhase 2

Biomarker Modulation and the Inhibition of Natural Killer Type 1 (NKT1) Cells by Oral GRI-0621 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks. Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers). An interim analysis will be performed when 24 subjects complete 6 weeks of treatment (approximately 8 placebo subjects).

Start Date24 Apr 2024

Sponsor / Collaborator

GRI Bio Operations, Inc.

CTRI/2023/11/060308 / Not yet recruitingNot ApplicableIIT

Comparative efficacy of different concentration of topical tazarotene and topical tretinoin in acne vulgaris. - NIL

Start Date05 Dec 2023

Sponsor / Collaborator-

CTRI/2023/10/059038 / RecruitingNot ApplicableIIT

Comparative efficacy of topical methotrexate and topical tazarotene in psoriasis vulgaris - NIL

Start Date31 Oct 2023

Sponsor / Collaborator

Government Medical College

100 Clinical Results associated with Tazarotene

100 Translational Medicine associated with Tazarotene

100 Patents (Medical) associated with Tazarotene

561

Literatures (Medical) associated with Tazarotene

18 Sep 2024·Clinical and Experimental Dermatology

Tazarotene is as effective and well-tolerated as imiquimod in the treatment of verruca plana: a comparative randomized controlled trial

Article

Author: Nofal, Hagar ; ElKholy, Basma ; Omran, Fatma ; Nofal, Ahmad ; Nofal, Sara

AbstractBackgroundPlane warts, when multiple and recurrent, present a therapeutic challenge acting as a source of reinfection, causing frustration and affecting a patient’s quality of life. For large numbers of lesions in cosmetically significant sites, topical treatment is preferred to avoid potential sequelae.ObjectivesTo evaluate and compare the efficacy and tolerability of tazarotene 0.1% gel vs. imiquimod 5% cream for the treatment of plane warts.MethodsIn a parallel three-arm randomized controlled trial, 60 patients were randomized to imiquimod, tazarotene or placebo groups. Patients applied the corresponding treatment once daily at night for a maximum of 12 weeks. Primary outcomes were the percentage of respondents with complete clearance in the three studied groups, and the type and frequency of side-effects in each group.ResultsBoth active treatments resulted in significant improvement compared with baseline and the placebo group (P = 0.001). The imiquimod 5% treated group showed complete clearance in 50% (10/20) of patients, partial response in 15% (3/20), and no response in 35% (7/20). Tazarotene 0.1% gel showed complete clearance in 40% (8/20) of patients, partial response in 40% (8/20), and no response in 20% (4/20). No significant difference was detected between the imiquimod and tazarotene groups (P = 0.19).ConclusionsCompared with imiquimod, tazarotene 0.1% gel for the treatment of plane warts seems to offer an equivalent treatment response, it maintained efficacy without recurrence and had a safer profile regarding dyspigmentation with an advantageous cheaper cost.

02 Sep 2024·Molecular Pharmaceutics

Correction to “Novel Synergistic Approach: Tazarotene-Calcipotriol-Loaded-PVA/PVP-Nanofiber Incorporated in Hydrogel Film for Management and Treatment of Psoriasis”

Author: Singh, Sanjay ; Anand, Sneha ; Kumar, Anand ; Jaiswal, Shweta ; Rajinikanth, Paruvathanahalli Siddalingam ; Thakur, Sunita ; Deepak, Payal ; Anjum, Md Meraj

01 Jul 2024·European Journal of Pharmaceutics and Biopharmaceutics

Formulation development of tazarotene-loaded PLGA nanoparticles for follicular delivery in the treatment of inflammatory skin diseases

Article

Author: Kipping, Thomas ; Kshirsagar, Sharvari M ; Banga, Ajay K ; Shrestha, Nisha

Tazarotene is a widely prescribed topical retinoid for acne vulgaris and plaque psoriasis and is associated with skin irritation, dryness, flaking, and photosensitivity. In vitro permeation of tazarotene was studied across the dermatomed human and full-thickness porcine skin. The conversion of tazarotene to the active form tazarotenic acid was studied in various skin models. Tazarotene-loaded PLGA nanoparticles were prepared using the nanoprecipitation technique to target skin and hair follicles effectively. The effect of formulation and processing variables on nanoparticle properties, such as particle size and drug loading, was investigated. The optimized nanoparticle batches with particle size <500 µm were characterized further for FT-IR analysis, which indicated no interactions between tazarotene and PLGA. Scanning electron microscopy analysis showed uniform, spherical, and non-agglomerated nanoparticles. In vitro release study using a dialysis membrane indicated a sustained release of 40-70 % for different batches over 36 h, following a diffusion-based release mechanism based on the Higuchi model. In vitro permeation testing (IVPT) in full-thickness porcine skin showed significantly enhanced follicular and skin delivery from nanoparticles compared to solution. The presence of tazarotenic acid in the skin from tazarotene nanoparticles indicated the effectiveness of nanoparticle formulations in retaining bioconversion ability and targeting follicular delivery.

News (Medical) associated with Tazarotene

14 Nov 2024

·www.globenewswire.com

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker study Topline data of GRI-0621 readout expected in Q2 2025 Currently available treatments for IPF are limited with only two approved drugs that come with significant side-effects, limited compliance and no impact on overall survival LA JOLLA, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the third quarter ended September 30, 2024 and provided a corporate update. “We continue to make fundamental progress on the development and regulatory fronts of our lead program GRI-0621 for the treatment of IPF. As we drive towards our interim data readout early next year, we are generating a robust and growing body of encouraging preclinical data with an innovative approach that we believe continues to validate and derisk our clinical approach,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio. “With our strengthened cash position and Phase 2a study execution, we believe we are poised to drive value for shareholders in both the near and long term.” Recent Highlights Presented positive preclinical data demonstrating GRI-0621’s ability to inhibit invariant Natural Killer T (iNKT) cell activity and reduce important inflammatory and fibrotic drivers in idiopathic pulmonary fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis in Athens, Greece;Expanded intellectual property protection for proprietary NKT cell modulators with granting of Japan patent titled, “Prevention and Treatment of Inflammatory Conditions;Received authorization to conduct Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in Australia; andParticipated in a Virtual Investor KOL Connect segment with prominent key opinion leader in IPF – Dr. Helen Parfrey, Respiratory Consultant at the Royal Papworth Hospital and Affiliated Assistant Professor at the University of Cambridge. GRI-0621: Type 1 Invariant NKT (iNKT) Antagonist in Development for the Treatment of IPF. IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream. Currently available treatments for IPF are limited with only two approved drugs that come with significant side-effects, limited compliance and no impact on overall survival1 leaving significant opportunity to augment IPF treatment with a new therapeutic. GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human iNKT cells. In preliminary trials to date and previous trials with the oral formulation, GRI-0621 has been shown to improve fibrosis in multiple disease models and improve liver function tests and other markers of inflammation and injury in patients. The Company plans to leverage the 505(b)(2) regulatory pathway. For more information about the Phase 2a study, please visit clinicaltrials.gov and reference identifier NCT06331624. Expected GRI-0621 Upcoming Milestones Q1 2025: Report interim data from Phase 2a biomarker studyQ2 2025: Report topline results from Phase 2a biomarker study Summary of Financial Results for Third Quarter 2024 Net loss was $6.3 million for the nine months ended September 30, 2024. Research and development expenses were $2.9 million and $2.2 million for the nine months ended September 30, 2024 and 2023, respectively. General and administrative expenses were $3.3 million and $7.2 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the Company had cash and cash equivalents of approximately $4.7 million. About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the Company’s expectations with respect to development and commercialization of the Company’s product candidates, the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company’s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials, the Company’s beliefs and expectations regarding potential shareholder value and future financial performance, the Company’s beliefs about the timing and outcome of regulatory approvals and potential regulatory approval pathways, the Company’s expected milestones for the first half of 2025 and the Company’s beliefs and expectations regarding the sufficiency of its existing cash and cash equivalents to fund its planned operations, its ability to raise additional funds, which may not be available to the Company on acceptable terms or at all, and capital expenditure requirements. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company’s common stock on Nasdaq and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company’s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company’s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) the failure to achieve any milestones or receive any milestone payments under any agreements; (10) inaccuracy in the Company’s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company’s ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (12) other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the risks and uncertainties described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 28, 2024 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775GRI@jtcir.com 1 T. M. Maher et al., Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res 22, 197 (2021)

Phase 2Financial StatementCell TherapyImmunotherapyPhase 1

25 Oct 2024

·www.prnewswire.com

Sun Pharma Announces Multiple Data Presentations Highlighting its Dermatology Portfolio to be Featured at the 2024 Fall Clinical Dermatology Conference

Data from a wide range of the Sun Pharma dermatology portfolio, including data on alopecia areata, psoriasis, acne and actinic keratosis products, will be highlighted during the meeting. MUMBAI, India and PRINCETON, N.J., Oct. 25, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced it will present more than a dozen posters at the 44th Annual Fall Clinical Dermatology Conference, being held October 24-27, 2024, in Las Vegas, Nevada. The presentations will include data from across the Sun Pharma dermatology portfolio, including study results for LEQSELVI™ (deuruxolitinib), WINLEVI® (clascoterone), ILUMYA® (tildrakizumab-asmn), ODOMZO® (sonidegib) and LEVULAN® KERASTICK® (aminolevulinic acid HCl) + BLU-U® (blue light photodynamic therapy). "As an organization dedicated to supporting the dermatology community, the Fall Clinical Dermatology Conference offers a vitally important forum to present new data and highlight how Sun's innovative dermatology portfolio can support those living with alopecia areata, psoriasis, acne and other skin-related diseases," said Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Development at Sun Pharma. "We look forward to sharing data from across our portfolio with the dermatology research community and our esteemed industry colleagues." Six abstracts, accepted for poster presentations, will highlight clinical efficacy and safety data of LEQSELVI™ (deuruxolitinib). Approved earlier this year by the U.S. Food and Drug Administration for the treatment of adults with severe alopecia areata, LEQSELVI™ is an oral JAK inhibitor that interrupts the pathways thought to contribute to hair loss in severe AA and delivered statistically significant efficacy at 24 weeks across two Phase 3 clinical trials. LEQSELVI™ data being presented at Fall Clinical showcase pooled long-term results for ongoing clinically meaningful improvements in scalp hair regrowth in adults with alopecia areata. Additionally, two posters will present patient and clinician preferences for the treatment of alopecia areata. The WINLEVI® poster presentations will include new data showing significant reductions in casual facial sebum levels from baseline, stability in the presence of other commonly prescribed acne medications, and efficacy and safety from a pilot study in patients with skin of color. The conference will also feature data from three additional WINLEVI® studies. Sun Pharma will present the following posters at the 2024 Fall Clinical Dermatology Conference: LEQSELVI™ Presentations: Deuruxolitinib results in ongoing clinically meaningful improvements in scalp hair regrowth in adults with alopecia areata: Pooled long-term efficacy and safety data from the open-label extension studies Patient Preferences for the Treatment of Alopecia Areata A Discrete Choice Experiment to Assess Clinician Preferences for the Treatment of Alopecia Optimization of deuruxolitinib dosing in adult patients with alopecia area: Results from a randomized, parallel-group, multicenter Phase 2 trial Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials WINLEVI® Presentations: Clinical evaluation of the sebum reduction induced by clascoterone cream 1%: Week 12 interim analysis Assessment of clascoterone cream 1% levels when layered with other topical acne medications Efficacy and safety of clascoterone cream 1% in patients with acne with skin of color: 16-week interim analysis The efficacy and safety of clascoterone cream 1% for the treatment of acne vulgaris are not dependent on patient age and sex: Results of a post hoc analysis Improvement in skin moisturization and lack of barrier damage with clascoterone cream 1% treatment: Results of a randomized, single-blind, split-face study in acne-prone individuals Comparison of the efficacy of clascoterone vs trifarotene and tazarotene for the treatment of acne vulgaris at Week 12: A systematic review and meta-analysis ILUMYA® Presentation: A systematic literature review and meta-analysis of the real-world effectiveness, quality of life, and safety of tildrakizumab for moderate-to-severe plaque psoriasis ODOMZO® Presentation: Lower rate of discontinuation of sonidegib compared to vismodegib in a real-world analysis of patients with basal cell carcinoma LEVULAN® KERASTICK® + BLU-U® Presentation: Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by blue light in the treatment of facial cutaneous squamous cell carcinoma in situ About Sun Pharmaceutical Industries Limited. (CIN – L24230GJ1993PLC019050) Sun Pharma is the world's leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit and follow us on LinkedIn & X (Formerly Twitter). Disclaimer: Statements in this "document" describing Sun Pharma's objectives, projections, estimates, expectations, plans or predictions, industry conditions, or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. Sun Pharma does not undertake any obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. SOURCE Sun Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Clinical ResultPhase 2

24 Oct 2024

·www.globenewswire.com

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) Current treatment options for IPF are limited with only 2 approved drugs which have significant side-effects, limited compliance and no impact on survival LA JOLLA, CA, Oct. 24, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that on October 22, 2024 it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 762,236 shares of the Company’s common stock originally issued by GRI Bio in February 2024. The gross proceeds to the Company from the exercise of warrants were approximately $0.8 million, prior to deducting placement agent fees and offering expenses payable by the Company. Including the gross proceeds from this offering, the Company has raised approximately $13.9 million in gross proceeds since the beginning of 2024. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The shares of common stock issued upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-276205). Marc Hertz, PhD, Chief Executive Officer of GRI Bio, commented, “The proceeds from the financings we have completed since the start of this year have greatly strengthened our balance sheet and are estimated to have provided the necessary funding to advance the development of our lead program into the middle of the first quarter of 2025. With these proceeds in hand and the continued progress toward interim and topline data for our lead program, expected in the coming quarters, we believe we are well positioned to realize the full potential of GRI-0621 to provide significant benefit to IPF patients.” In consideration for the immediate exercise of the existing warrants for cash, the Company issued new unregistered Series D-1 warrants to purchase up to an aggregate of 762,236 shares of the Company’s common stock and new unregistered Series D-2 warrants to purchase up to an aggregate of 762,236 shares of the Company’s common stock. The new Series D-1 and D-2 warrants are immediately exercisable at an exercise price of $1.00 per share. The Series D-1 warrants will have a term of five years from the issuance date and the Series D-2 warrants will have a term of eighteen months from the issuance date. The new Series D-1 and D-2 warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of common stock issuable upon exercise of the new warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the new warrants issued in the private placement and the shares of common stock issuable upon the exercise of the new warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, the Company’s expectations with respect to development and commercialization of the Company’s product candidates, the timing of initiation or completion of clinical trials and availability of resulting data, potential acceleration of enrollment, the potential benefits and impact of the Company’s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials, the Company’s beliefs and expectations regarding potential stakeholder value and future financial performance, the Company’s beliefs about the timing and outcome of regulatory approvals and potential regulatory approval pathways, the Company’s expected milestones for 2024 and 2025, including the potential availability of clinical trial data, and the Company’s beliefs and expectations regarding the sufficiency of its existing cash and cash equivalents to fund its operating expenses and capital expenditure requirements and its estimated cash runway. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) market and other conditions; (2) the inability to maintain the listing of the Company’s common stock on Nasdaq and to comply with applicable listing requirements; (3) changes in applicable laws or regulations; (4) the inability of the Company to raise financing in the future; (5) the success, cost and timing of the Company’s product development activities; (6) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (7) the inability of the Company to identify, in-license or acquire additional technology; (8) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (9) the size and growth potential of the markets for the Company’s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (10) the failure to achieve any milestones or receive any milestone payments under any agreements; (11) inaccuracy in the Company’s estimates regarding expenses, future revenue, capital requirements, the availability of clinical trial data, cash runway and the ability to obtain additional financing; (12) the Company’s ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (13) other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the risks and uncertainties described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 28, 2024 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Investor Contact: JTC Team, LLCJenene Thomas(908) 824-0775GRI@jtcir.com

Phase 2Cell TherapyImmunotherapy

100 Deals associated with Tazarotene

External Link

KEGG	Wiki	ATC	Drug Bank
D01132	Tazarotene	D05AX05	DB00799

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Facial wrinkles	US	Allergan, Inc.	30 Sep 2002
Hyperpigmentation	US	Allergan, Inc.	30 Sep 2002
Acne Vulgaris	US	Allergan, Inc.	13 Jun 1997
Plaque psoriasis	US	Allergan, Inc.	13 Jun 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Idiopathic Pulmonary Fibrosis	Phase 2	US	GRI Bio Operations, Inc.	24 Apr 2024
Idiopathic Pulmonary Fibrosis	Phase 2	GB	GRI Bio Operations, Inc.	24 Apr 2024
Chronic liver disease	Phase 1	ZA	GRI Bio Operations, Inc.	01 Sep 2015
Acne Vulgaris	Preclinical	BZ	Actavis, Inc.	01 Jun 2014
Arthritis, Psoriatic	Preclinical	DE	Almirall SA	01 Feb 2014
Psoriasis of nail	Preclinical	DE	Almirall SA	01 Feb 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04071756 (CTgov)	Phase 2	Solid tumor \| Hand-Foot Syndrome	8	Topical Tazarotene (Topical Tazarotene 0.1% Gel Plus BPS)	dapvqkonqf(twerrgucew) = vrdlvxawnz anplbblici (wcavurwocq, yxfcmzohzx - eymbpwmrfg) View more	-	15 Nov 2023
				Placebo (Placebo Gel Plus BPS)	dapvqkonqf(twerrgucew) = mmngvmfvqo anplbblici (wcavurwocq, jqgyawoyre - wipedbehtw) View more
WCD2023	Not Applicable	Onychomycosis	20	Topical 0.1% tazarotene gel	ltvpgxhekr(kjkhcuawwx) = jnmswmpmhe widrnyrzzl (agitetaudq )	Positive	07 Jul 2023
AAD2023	Not Applicable	Photodamaged skin	18	Tazarotene 0.045% Lotion	dzvqqpopjj(wseczypcor) = llywrivnnt lukkobgwtm (wyevmxkllw )	-	17 Mar 2023
AAD2023	Not Applicable	Psoriasis interleukin 17A	10	Fixed-Combination Halobetasol Propionate and Tazarotene Topical Lotion	qjbrwacptt(iczrpoaqca) = szlwjuzjvo bhofltqjxc (sjqgmxrmwa )	-	17 Mar 2023
EADV2022	Not Applicable	Plaque psoriasis	-	Calcipotriol 0.005% plus betamethasone dipropionate 0.064% foam	vvkmfydxns(pbuprkedgh) = 0.8%/0.1% vs 7.4% yuvjtpptsp (xxyfbdwivx ) View more	-	12 May 2022
				Halobetasol propionate 0.01% plus tazarotene 0.045% lotion
NCT03168321 (CTgov)	Phase 3	Acne Vulgaris	813	IDP-123 Lotion	wxrxfjftpc(lylakmcqlr) = vounniekwj zqyfwmwfjy (ybqmzlimws, ggboopqtvf - qhlnknqilw) View more	-	01 Apr 2021
NCT03599193 (CTgov)	Phase 2	Acne Vulgaris	58	Tazarotene Lotion, 0.1% (DFD-03 Lotion)	(mbzifzftnl) = pxeaamgkgi qhkbaylaow (uqbimuifgr, kahicdjtwa - uvttdzqmww) View more	-	14 Sep 2020
				Tazarotene Cream, 0.1% (Tazorac Cream)	(mbzifzftnl) = wzvfnjknke qhkbaylaow (uqbimuifgr, bnhhlaauwe - rykjqhzbzk) View more
NCT03292640 (CTgov)	Phase 3	Acne Vulgaris	547	DFD-03 (0.1% tazarotene) Lotion (DFD-03 Lotion (0.1% Tazarotene))	wfxucjxdzc(bdqcwexvix) = oggfhdlrft mzywtumxza (czgxzfawlq, uroqpqzyun - tuuzqaeoxz) View more	-	09 Jun 2020
				DFD-03 (0% tazarotene) Lotion (Placebo) (DFD-03 Vehicle (0% Tazarotene))	wfxucjxdzc(bdqcwexvix) = bjxolbrbhq mzywtumxza (czgxzfawlq, ywslvlprpr - hezuziorln) View more
NCT03290027 (DFD-03, CTgov)	Phase 3	Acne Vulgaris	550	DFD-03 (Active)	ulyhechxvs(ffjwzpoedd) = ewhgegbfxv zqkrtzwgme (ypnctoyaup, qmitbgzmwp - yznaykzrun) View more	-	26 May 2020
				Placebo Comparator (Vehicle)	ulyhechxvs(ffjwzpoedd) = jpmvhehqyj zqkrtzwgme (ypnctoyaup, sjylaxgzfa - pepgsuuusq) View more
NCT02886702 (CTgov)	Phase 3	Plaque psoriasis	855	Tazarotene Cream 0.05% (Test)	mhbwydezzg(babunqcfhy) = fumzwjeyvl afljuqxlwi (mitcnkgvpj, tagjxoaxbd - vucyeikzvj) View more	-	29 Aug 2018
				TAZORAC® (tazarotene) Cream 0.05% (Reference)	mhbwydezzg(babunqcfhy) = zyiymwsurf afljuqxlwi (mitcnkgvpj, lurxojpwih - zkolnvqbrf) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis